Logo image of CMND

CLEARMIND MEDICINE INC (CMND) Stock Fundamental Analysis

USA - NASDAQ:CMND - CA1850534027 - Common Stock

1.02 USD
-0.03 (-2.86%)
Last: 9/12/2025, 8:00:00 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CMND. CMND was compared to 195 industry peers in the Pharmaceuticals industry. CMND has a bad profitability rating. Also its financial health evaluation is rather negative. CMND does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CMND had negative earnings in the past year.
CMND had a negative operating cash flow in the past year.
In the past 5 years CMND always reported negative net income.
In the past 5 years CMND always reported negative operating cash flow.
CMND Yearly Net Income VS EBIT VS OCF VS FCFCMND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

CMND's Return On Assets of -75.30% is on the low side compared to the rest of the industry. CMND is outperformed by 69.90% of its industry peers.
Looking at the Return On Equity, with a value of -173.75%, CMND is doing worse than 68.88% of the companies in the same industry.
Industry RankSector Rank
ROA -75.3%
ROE -173.75%
ROIC N/A
ROA(3y)-350.52%
ROA(5y)-233.83%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CMND Yearly ROA, ROE, ROICCMND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

CMND does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMND Yearly Profit, Operating, Gross MarginsCMND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, CMND has more shares outstanding
CMND has more shares outstanding than it did 5 years ago.
CMND has a worse debt/assets ratio than last year.
CMND Yearly Shares OutstandingCMND Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
CMND Yearly Total Debt VS Total AssetsCMND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

CMND has an Altman-Z score of -6.22. This is a bad value and indicates that CMND is not financially healthy and even has some risk of bankruptcy.
CMND has a worse Altman-Z score (-6.22) than 62.76% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that CMND is not too dependend on debt financing.
The Debt to Equity ratio of CMND (0.00) is better than 62.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.22
ROIC/WACCN/A
WACCN/A
CMND Yearly LT Debt VS Equity VS FCFCMND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M -6M

2.3 Liquidity

CMND has a Current Ratio of 1.72. This is a normal value and indicates that CMND is financially healthy and should not expect problems in meeting its short term obligations.
CMND has a worse Current ratio (1.72) than 64.29% of its industry peers.
A Quick Ratio of 1.72 indicates that CMND should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.72, CMND is in line with its industry, outperforming 41.84% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.72
Quick Ratio 1.72
CMND Yearly Current Assets VS Current LiabilitesCMND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 91.77% over the past year.
EPS 1Y (TTM)91.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CMND. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMND Price Earnings VS Forward Price EarningsCMND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMND Per share dataCMND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CMND does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLEARMIND MEDICINE INC

NASDAQ:CMND (9/12/2025, 8:00:00 PM)

1.02

-0.03 (-2.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners10.91%
Inst Owner Change-2.05%
Ins Owners3.37%
Ins Owner Change0%
Market Cap5.49M
AnalystsN/A
Price TargetN/A
Short Float %4.8%
Short Ratio0.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.92
P/tB 2
EV/EBITDA N/A
EPS(TTM)-1.2
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.87
FCFYN/A
OCF(TTM)-0.87
OCFYN/A
SpS0
BVpS0.53
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -75.3%
ROE -173.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-350.52%
ROA(5y)-233.83%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.72
Quick Ratio 1.72
Altman-Z -6.22
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)91.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.23%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.21%
OCF growth 3YN/A
OCF growth 5YN/A